SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community discusses potential catalysts including upcoming ETFs and treasury investments. Optimism is high, with some anticipating a continued surge, while others caution about potential pullbacks and resistance levels. Traders are closely watching key price levels and discussing strategies around long-term holds.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending amid overall positive sentiment in the crypto market and speculation around potential ETF approvals, with the community actively discussing new memecoins and potential price targets. News of Galaxy Digital acquiring a substantial amount of SOL has further fueled optimism, as the community anticipates significant growth and adoption within the Solana ecosystem.

Pump.fun

$PUMP.X is gaining traction as traders discuss its potential within the meme coin space, with some anticipating significant gains and highlighting its role as a platform on Solana. Community members are actively sharing positive sentiment, discussing entry points, and expressing excitement about the project's future. Despite the enthusiasm, some caution against potential risks associated with meme coins and the overall volatility in the crypto market.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid heated discussions around political polarization and its potential connection to real-world events. The community is focused on assigning blame and interpreting motives, with some pointing fingers across the political spectrum. Broader conversations encompass social media's influence and the impact of political rhetoric.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) $DOG.X is trending as the community rallies behind its fair distribution and Bitcoin-native status, contrasting it with other meme coins. Community members highlight its strong ties to the Bitcoin blockchain and organic growth, emphasizing its potential as the leading meme coin in the Bitcoin ecosystem. The #DOGArmy is actively promoting the ticker and celebrating its position as a top trending crypto.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining attention as discussions emerge around real world asset (RWA) adoption and its potential to disrupt the market data industry. The community is closely watching price movements and anticipating the next leg up, while also considering the impact of broader market forces and potential partnerships. Some users are pointing out negative funding rates.

Cardano is a proof-of-stake blockchain platform designed to support decentralized applications (dApps), featuring a multi-asset ledger and smart contract functionality. Unlike many other blockchains, Cardano is built from the ground up based on original academic research, with proposed solutions undergoing peer review and presentation at international conferences before development. The platform emphasizes a research-driven and formal methods approach to design and implementation.

Cardano

Cardano is trending amidst discussions about potential ETF approvals and overall market performance compared to other cryptocurrencies. Community members are actively debating its future price potential and real-world use cases, including projects on the Cardano chain. Some traders are watching key technical levels, anticipating a significant price movement.

Bridging Real World Asset (RWA) With Blockchain. Own, Invest and Earn Through NFTs on #Solana.

Sky Hause

Sky Hause ($SKYH.X) is trending as community members discuss its potential for a significant breakout, with many emphasizing the opportunity for early entry. The conversation highlights the idea that a surge could happen unexpectedly following a period of quiet accumulation. However, some users warn to be cautious about potential scams.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG is trending as the community rallies around this Bitcoin-based memecoin, emphasizing its fair distribution, strong community, and unique position on the Bitcoin network. Discussions highlight its potential to outperform other memecoins and challenge the traditional crypto market structure by not relying on insiders or paid promotions. The community refers to itself as the DOG Army, expressing conviction that $DOG is the future.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis (AVNT.X) is trending as the community discusses its recent price action and potential for further gains, with some comparing it to other hyped tokens.  Many traders are watching key levels and anticipating a continued run, while also noting its backers and potential for real-world asset trading. The project's fundamentals and market cap relative to competitors are also being weighed.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of InMed Pharmaceuticals surged to levels not seen in nearly five months, capturing significant attention from retail investors.&nbsp;The biopharma company, with a market cap of just under $4 million, announced on Tuesday that its INM-901 small molecule drug candidate for Alzheimer's disease demonstrated promising results in a recent clinical trial.The study showed that INM-901 significantly reduced several markers of neuroinflammation, both in plasma and the brain.&nbsp;Specifically, the high-dose treated group exhibited a dose-dependent reduction in pro-inflammatory cytokines and neurofilament light chain levels in the plasma.&nbsp;Additionally, the trial indicated a reduction in key neuroinflammatory genes in the brain, signaling a potential breakthrough in Alzheimer's treatment.Eric Hsu, InMed's Senior Vice President of Preclinical R&amp;D, expressed excitement over the results, noting, "The ability of INM-901 to actively reduce inflammation is an exciting development, as neuroinflammation has emerged as a promising new drug target beyond existing AD treatments focused primarily on removing amyloid beta plaques and tau protein tangles."&nbsp;He added, "INM-901 may address multiple pathological factors, making it a very promising drug candidate."The positive trial results propelled InMed into the top 25 trending stocks on Stocktwits, with a flood of bullish comments on the platform.&nbsp;One user expressed happiness with the stock's surge and speculated on the potential for a buy-out.<stembedurl>https://stocktwits.com/pennyman/message/600871159</stembedurl>Another suggested that InMed's current levels were too good an entry point to miss.<stembedurl>https://stocktwits.com/AmbushPredator/message/600878277</stembedurl>According to Koyfin data, InMed has only about 718,000 shares outstanding and a short interest of 1.3%.&nbsp;While <a href="https://stocktwits.com/symbol/INM">InMed's stock</a> is down nearly 30% over the past 12 months, it has gained approximately 14% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise

The positive trial results propelled InMed into the top 25 trending stocks on Stocktwits, with a flood of bullish comments on the platform. 

Equity

The positive trial results propelled InMed into the top 25 trending stocks on Stocktwits, with a flood of bullish comments on the platform. 


EXCLUSIVE: New Alzheimer's Treatment? Promising Cannabinoid Compound Shows Hope, InMed CEO Says

InMed Pharmaceuticals is making strides in Alzheimer's research with its development of a cannabinoid-based compound.
read more...

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathwayIn Vivo studies demonstrate INM-901 reduces neuroinflammation and improves...

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ('InMed' or the 'Company'), a leader in the manufacturing, development and commercialization...

InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying

The Dow Jones index closed higher by over 450 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

Advancing two new preclinical programs in Alzheimer's and Age-Related Macular DegenerationClosed calendar year 2023 with cash position of US$9.5 million164% revenue growth in the commercial BayMedica...

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ('InMed' or the 'Company'), a leader in the manufacturing, development and...

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ('InMed' or the 'Company'), a leader in the manufacturing, development and...

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

Advancing INM-901 as a multimodal treatment option for Alzheimer's DiseaseAdvancing INM-089 in the treatment of Age-related Macular DegenerationActively seeking partnerships to advance INM-755 in...

InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. It operates through the InMed Pharma and BayMedica segments. The InMed Pharma segment is organized around the research and development of small molecule pharmaceuticals drug candidates. The BayMedica segment focuses on the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. It is also involved in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

INM
InMed Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INM News

INM InMed Pharmaceuticals Inc